Adherence to antiretroviral therapy

AIDS Reviews

Volumn 3, Issue 3, 2001, Pages 111-120

  Friedland, G H ^a   Andrews, L A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Antiretroviral therapy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COST BENEFIT ANALYSIS; DOCTOR PATIENT RELATION; DOSE CALCULATION; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; FACTORIAL ANALYSIS; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; OUTCOMES RESEARCH; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; STATISTICS; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0035205067     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. The care of HIV-infected adults in the United States
3. Further characterizing determinants of disease progression among HIV-1 infected patients initiating triple drug therapy
4. Adherence in patients treated with HAART: Influence in hospital admissions
5. The era of adherence to HIV therapy
6. Errors in prescribing HIV-1 protease inhibitors
7. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
8. Viral dynamics of HIV: Implications for drug development and therapeutic strategies
9. Attaining higher goals in HIV treatment: The central importance of adherence
10. Antiretroviral therapy for HIV infection in 2000: Updated recommendations of the International AIDS Society-USA Panel
11. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS trial
12. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
13. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection
14. Three-year durability of response with an efavirenz (EFV) containing regimen: 144 week follow-up from study 006
15. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
16. Adherence to antiretroviral medications in an inner-city population
17. Clinical, immunological and virological effectiveness of antiretroviral therapy in a resource-poor setting: The Senegalese Experience
18. Initial data on antiretroviral adherence in Cape Town, South Africa
19. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
20. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
21. Impact of directly observed therapy on outcomes in HIV clinical trials
22. Self-reported antiretroviral adherence levels correlate with HIV viral load and decline over time
23. Non-adherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women
24. Antiretroviral adherence and its consistency predict biologic outcomes in HIV clinical trials
25. Public health implications of antiretroviral therapy and HIV drug resistance
26. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and non-nucleoside reverse transcriptase inhibitors
27. Viral load and heterosexual transmission of human immunodeficiency virus type 1
28. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
29. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
30. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel
31. Correlates of risky behaviors among young and older men having sexual relations with men in Montreal, Quebec, Canada
32. Combination therapies for HIV a sexual risk behavior among gay men
33. Behavioral and biologic evidence of persistent high-risk behavior in a HIV primary care population
34. Sexual behavior changes and protease inhibitor therapy
35. Frequency, patterns and correlates of HIV transmission risk behaviors among HIV seropositive patients in clinical care
36. A comparison study of multiple measures of adherence to HIV protease inhibitors
37. The magnitude of compliance and non-compliance
38. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial
39. Adherence and viral load in HIV infected drug users: Comparison of self-report and medication event monitors (MEMS)
40. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments
41. HIV-1 viral load, and development of drug resistance in an indigent population
42. Serum protease inhibitor level as a marker of adherence to HAART: Correlation with self-reported adherence and with HIV RNA
43. Patient-reported non-adherence to HAART is related to protease inhibitor levels
44. Response to ritonavir (RTV) intensification in indinavir (IDV) recipients in highly correlated with virtual inhibitory quotient
45. A critical review of the "determinants" of patient compliance with therapeutic regimens
46. Adherence in AIDS clinical trials: A framework for clinical research and clinical care
47. Stages and processes of self-change of smoking: Toward an integrative model of change
48. Changing AIDS-risk behavior
49. A method for assessing patient readiness to begin and adhere to highly active antiretroviral therapy (HAART)
50. Readiness for antiretroviral therapy and correlates with durable viral suppression
51. Trust and the acceptance of and adherence to antiretroviral therapy
52. Physician-patient communication and patient conformity with medical advice
53. Adherence to combination antiretroviral therapies in HIV patients of low health literacy
54. Patient characteristics and attitudes associated with antiretroviral adherence
55. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility
56. Zidovudine adherence among individuals with HIV infection
57. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: A cross-sectional study in a municipal hospital clinic
58. AIDS in Blackface
59. Variations in patient compliance with doctor's advice: An empirical analysis of patterns of communication
60. Intravenous drug use: Relationship with providers, and stage of HIV disease influence the prescription rate of protease inhibitors
61. Adherence to antiretroviral regimens in HIV-infected patients: Results of a survey among physicians and patients
62. Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications
63. Effectiveness of interventions to improve patient compliance - A meta analysis
64. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy
65. Strategies to optimize adherence to highly active antiretroviral treatment
66. Adherence to zidovudine (AZT) among HIV-infected methadone patients: A pilot study of supervised therapy and dispensing compared to usual care
67. Adherence to HAART in French HIV-injecting drug users: The contribution of buprehnorphine drug maintenance treatment
68. The impact of the ALR™ alarm device on antiretroviral (AR) adherence among HIV-infected outpatients in Harlem
69. Intervention trial using a novel electronic device in HAART initiators: Impact of cognitive dysfunction
70. Cue-dose training with monetary reinforcement: A pilot study of an antiretroviral adherence intervention
71. A randomized controlled trial of interventions to improve adherence to antiretroviral therapy (CPCRA 062)
72. Study improved adherence to antiretroviral therapy at 6 months in HIV-1 infected individuals: Impact of face-to-face treatment education program: The Ciel Bleu Study
73. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis
74. High-compliance tuberculosis treatment programme in a rural community (Public Health)
75. The feasibility of directly observed therapy (DOT) among HIV+ substance users: A pilot study
76. Once a day treatment for HIV infection: Final 48 week results
77. Once daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients